QUEBEC CITY, Oct. 3, 2018 /CNW Telbec/ - Opsens Inc.
("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) will host an investor webinar and live Q&A
session on
Thursday, October 4, 2018, at 4.05 p.m.
EST.
The webinar will feature a presentation by Louis Laflamme, President and CEO of Opsens, who
will discuss Opsens' high-performance proven technology, its market opportunity, its competitive advantages in interventional
cardiology, more specifically in Fractional Flow Reserve (FFR), and other key developments.
To view the webinar, please visit https://www.redchip.com/events/31/opsens-webinar.
About Opsens Inc. (www.opsens.com or www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR and dPR in interventional cardiology. Opsens offers an advanced optical-based
pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product,
the OptoWire, is a 2nd-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry
and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 40,000 patients in more than 30
countries. It is approved for sale in the United States, European Union, Japan, and Canada.
Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing
solutions for critical applications.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance and achievements of Opsens to be materially different from any future results,
performance or achievements expressed or implied by the said forward-looking statements.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE OPSENS INC.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2018/03/c7471.html